Prilactone®, the world's first aldosterone antagonist licensed for the treatment of canine heart disease, has been introduced by CEVA Animal Health.
Clinical trials have demonstrated that the product, which contains spironolactone…
Ceva Animal Health has announced the launch of Cardalis for the treatment of canine heart failure caused by degenerative valvular heart disease.
Cardalis contains what the company says is a unique combination of benazepril and spironolactone in one…
Ceva Animal Health has launched a competition - open to veterinary surgeons and nurses - to support Cardalis (benazepril and spironolactone), its dual-acting treatment for heart failure in dogs.
To enter the competition, which will run till the end…
Ceva Animal Health has launched Libeo, a new four-way break, palatable furosemide for the management of heart failure in dogs.
According to the company, furosemide - a diuretic - is the most frequently used treatment for the management of heart failure…
Ceva Animal Health has launched Amodip, described as the first ever cat-friendly amlodipine licensed for veterinary use for the treatment of hypertension in cats.
Amodip is a chicken-flavoured, two-way break chewable tablet; its 1.25mg tablet size is…
Prilactone Next is replacing the spironolactone…
The new drug represents the fruit of 8 years of product development and…